1	A comprehensive evaluation of polygenic score methods across				
2	cohorts in psychiatric disorders				
3					
4	Authors:				
5	Guiyan Ni, <sup>1</sup> Jian Zeng, <sup>1</sup> Joana A Revez, <sup>1</sup> Ying Wang, <sup>1</sup> Tian Ge, <sup>2</sup> Restaudi Restaudi, <sup>1</sup>				
6	Jacqueline Kiewa, <sup>1</sup> Dale R Nyholt, <sup>3</sup> Jonathan R I Coleman, <sup>4</sup> Jordan W Smoller, <sup>5,2,6</sup>				
7	Schizophrenia Working Group of the Psychiatric Genomics Consortium, <sup>7</sup>				
8	Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, <sup>8</sup>				
9	Jian Yang, <sup>1</sup> Peter M Visscher, <sup>1</sup> Naomi R Wray <sup>1,9</sup>				
10					
11	1. Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, 4072,				
12	Australia				
13	2. Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General				
14	Hospital, Boston, MA, 02114, US				
15	3. Faculty of Health, School of Biomedical Sciences, Centre for Genomics and Personalised				
16	Health, Queensland University of Technology, Brisbane, Queensland, 4000, Australia				
17	4. Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology,				
18	and Neuroscience, King's College London, London, SE58AF United Kingdom				
19	5. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, 02114, US				
20	6. Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, 02142, US				
21	7. A list of members and affiliations appears in the Supplementary Data.				
22	8. A list of members and affiliations appears in the Supplementary Data.				
23	9. Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, 4072,				
24	Australia				

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 25 Correspondence:

26 \*Naomi R Wray: naomi.wray@uq.edu.au

#### 27 Abstract:

28 Polygenic scores (PGSs), which assess the genetic risk of individuals for a disease, are 29 calculated as a weighted count of risk alleles identified in genome-wide association studies 30 (GWASs). PGS methods differ in terms of which DNA variants are included in the score and 31 the weights assigned to them. PGSs are evaluated in independent target samples of 32 individuals with known disease status. Evaluation of new PGS methods are made using 33 simulated data or single target cohort, however, in real data sets there can be heterogeneity 34 between target sample cohorts, which could reflect a number of real or artefactual factors. 35 The Psychiatric Genomics Consortium working groups for schizophrenia (SCZ) and major 36 depressive disorder (MDD) bring together many independently collected case-control cohorts 37 for GWAS meta-analysis. These resources are used here in repeated application of leave-one-38 cohort-out GWAS analyses, generating robust conclusions for PGS prediction applied across 39 multiple target (left-out) cohorts. Eight PGS methods (P+T, SBLUP, LDpred-Inf, LDpredfunct, LDpred, PRS-CS, PRS-CS-auto, SBayesR) are compared. We found that SBayesR had 40 41 the highest prediction evaluation statistics in most comparisons. For SCZ across 30 target 42 cohorts, the SBayesR PGS achieved a mean area under the receiver operator characteristic curve (AUC) of 0.733, and explained 9.9% of variance on the liability scale. For MDD across 43 44 26 target cohorts, the AUC and variance explained were 0.601 and 4.0%, respectively. The 45 variance explained by the SBayesR PGS was 46% and 43% higher for SCZ and MDD, 46 respectively, compared to the basic p-value thresholding P+T method.

47

#### 48 Introduction

49

50	Polygenic scores (PGSs), which assess the genetic risk of individuals for a disease <sup>1; 2</sup> , are
51	calculated as a weighted count of genetic risk alleles in the genome of an individual, with the
52	risk alleles and their weights typically derived from the results of genome-wide association
53	studies (GWAS). <sup>3</sup> PGS can be calculated for any trait or disease with sufficiently powered
54	GWAS ('discovery samples'). For many common complex genetic disorders, such as
55	cancers <sup>4; 5</sup> and heart disease <sup>6; 7</sup> , there is increasing interest in trialling PGS for early disease
56	detection, prevention and intervention <sup>8; 9</sup> . In the context of psychiatric disorders, it has been
57	argued <sup>10</sup> that PGS may have utility in the context of youth mental health clinics, where young
58	people present with symptoms that have not yet crystallised to portray a clear treatment
59	pathway. A high PGS could nudge clinic decision making for those presenting in this
60	prodromal state.

61

62 There are now many methods to calculate PGSs, and the methods differ in terms of two key 63 criteria: which DNA variants to include (DNA variants here are limited to single nucleotide 64 polymorphisms, SNPs, but can include other DNA variants tested for association with a trait) 65 and what weights to allocate to them. While stringent thresholds are set to declare 66 significance for association of individual SNPs in GWAS, PGSs are robust to inclusion of 67 some false positives, and the maximum prediction from PGSs tested in target samples (i.e., 68 GWAS samples independent of the GWAS discovery sample) may include nominally 69 associated SNPs. The optimum method to decide which SNPs to select and what weights to 70 allocate them, may differ between traits depending on the sample size of the discovery 71 GWAS and on the genetic architecture of the trait (the number, frequencies and effect sizes 72 of causal variants), particularly given the linkage disequilibrium (LD) structure between

73 SNPs. Often, when new PGS methods are introduced, comparisons are made between a 74 limited set of methods using simulated data, together with application to some real data 75 examples. However, it can be difficult to compare across the new methods, particularly 76 because in real data there can be heterogeneity in PGS evaluation statistics between target 77 samples, not encountered in idealised simulations. The reasons for this heterogeneity are 78 usually unknown but could reflect a number of factors such as phenotype definition, 79 ascertainment strategies of cases and controls, cohort-specific ancestry within the broad 80 classification of ancestry defined by the GWAS discovery samples (e.g., European), or 81 technical artefacts in genotype generation.

82

83 Here, we compare eight PGS methods (P+T<sup>3; 11</sup>, SBLUP<sup>12</sup>, LDpred-Inf<sup>13</sup>, LDpred<sup>13</sup>, LDpredfunct<sup>14</sup>, PRS-CS<sup>15</sup>, PRS-CS-auto<sup>15</sup> and SBayesR<sup>16</sup> in Table 1 ). Some of these methods (P+T, 84 85 LDpred and PRS-CS) require a tuning sample, a GWAS cohort with known trait status that is independent of both discovery and target samples, used to select parameters needed to 86 87 generate the PGSs in the target sample. Briefly, P+T (pruning with a p-value threshold) uses the GWAS effect size estimates as SNP weights and includes independent SNPs (defined by 88 an LD  $r^2$  filter for a given chromosomal window distance) with association p-values lower 89 90 than a threshold (chosen after application in a tuning sample). P+T is the most commonly 91 used and basic method, and so is the bench-mark method here. The other methods (referred to 92 here as recent methods) assume either that all SNPs have an effect size drawn from a normal 93 distribution (SBLUP and LDpred-Inf) or that SNP effects are drawn from mixtures of 94 distributions with the key parameters defining these architectures estimated through Bayesian 95 frameworks (LDpred, PRS-CS, SBayesR). LDpred-funct includes functional annotation to 96 SNPs to up/down weight their contributions to the PGSs, which could improve prediction 97 accuracy if this functional information helps to better separate true and false positive

98	associations <sup>17</sup> . We apply these methods to data from the Psychiatric Genomics Consortium
99	(PGC) working groups for schizophrenia (SCZ) <sup>18; 19</sup> and major depressive disorder (MDD) <sup>20</sup>
100	<sup>22</sup> (Tables S1 and S2). The PGC provides a useful resource for undertaking this study
101	because it brings together many independently collected cohorts for GWAS meta-analysis.
102	This allows the application of repeated leave-one-cohort-out GWAS analyses generating
103	robust conclusions from evaluation of PGS applied across multiple left-out target cohorts.

#### 104 Materials and Methods

105 Data:

106 Schizophrenia GWAS summary statistics, denoted as PGC-SCZ2+, were available from PGC 107 Schizophrenia (SCZ) Working group (34 European ancestry cohorts, denoted as SCZ34)<sup>18</sup> and another three cohorts from Pardiñas et al<sup>19</sup>. PGC-SCZ2+ comprises more than 8M 108 109 imputed SNPs in 31K SCZ cases and 41K controls. Individual level genotype data were 110 available from 25K cases and 30K controls of SCZ34. Detailed information about the cohorts is provided elsewhere<sup>23</sup> but is summarised in **Table S1**. Since some methods require a tuning 111 112 sample (defined below), we arbitrarily chose the lie2 cohort (137 cases and 269 controls) as the tuning cohort. The GWAS discovery sample was a meta-analysis of 35 cohorts; lie2 was 113 114 always excluded and then each of the remaining 33 cohorts was left-out in turn and used as 115 the target sample. In sensitivity analyses, investigating the impact of the tuning sample, the 116 msaf, gras and swe6 cohort were exchanged with lie2 in turn, in which msaf has a similar sample size as lie2, 327 cases and 139 controls, while gras and swe6 are larger with more 117 118 than 2000 individuals each.

119

Major depression GWAS summary statistics were available from seven studies including UK
Biobank<sup>21; 24</sup>, 23andMe<sup>25</sup>, GERA<sup>26</sup>, iPSYCH<sup>27</sup>, deCODE<sup>28</sup>, GenScotland<sup>29; 30</sup>, and the PGC

122	Major Depressive Disorder (MDD) Working group (with the data previously denoted as
123	PGC29, but here MDD29) <sup>20</sup> . All are European ancestry studies and comprise almost 13M
124	imputed SNPs from 248K cases and 563K controls. MDD29 includes the GWAS results from
125	29 research study cohorts. Detailed information of the MDD29 cohorts is described
126	elsewhere <sup>20; 21; 25-30</sup> but is summarised in <b>Table S2</b> . Individual level genotype data were
127	available for 15K cases and 24K controls from 26 cohorts. We left one cohort out of those 26
128	cohorts in turn as the target sample. A cohort from Muenster <sup>20</sup> , not included in the MDD29
129	was used as the tuning sample (845 clinical defined MDD cases and 834 controls). We then
130	meta-analysed with the other GWAS summary statistics results to make the discovery
131	samples. We note that the discovery sample meta-analyses include samples where the
132	depression phenotype is self-reported rather than following a structured clinical interview,
133	nonetheless we refer to the prediction as MDD since the PGC target cohorts are of MDD
134	cases and controls. 959 overlapped individuals between UK Biobank and MDD29 were
135	excluded from the target cohorts.
136	
137	The datasets stored in the PGC central server follow strict guidelines with local ethics
138	committee approval.
139	
140	Baseline SNP selection
141	For baseline analyses, only SNPs with minor allele frequency (MAF) > 0.1 and imputation
142	INFO score $> 0.9$ (converted to best-guess genotype values of 0, 1 or 2) were selected.
143	Sensitivity analyses relaxed the MAF threshold to $MAF > 0.05$ or 0.01 and INFO score
144	threshold to 0.3. All methods were conducted using HapMap3 SNPs, except the method P+T,
145	which was conducted based on all imputed SNPs (8M in SCZ, and 13M in MDD).
146	

#### 147 Prediction methods

We define a PGS of an individual, j, as a weighted sum of SNP allele counts:  $\sum_{i=1}^{m} \hat{b}_i x_{ij}$ , 148 where m is the number of SNPs included in the predictor,  $\hat{b}_i$  is the per allele weight for the 149 SNP,  $x_{ij}$  is a count of the number (0, 1, or 2) of trait-associated alleles of SNP *i* in individual 150 j. The cohort (target sample) for which PGSs are calculated is excluded from the meta-151 152 analysis that generates the GWAS summary statistics (discovery sample), so that discovery and target samples are independent. We compared eight risk prediction methods (detailed 153 154 below): The methods differ in terms of the SNPs selected for inclusion in the predictor and the  $\hat{b}_i$  values assigned to the SNPs. All methods use the GWAS summary statistics as the 155 starting point, but each makes choices differently for which SNPs to include and for the  $\hat{b}_i$ 156 157 values to assign. Briefly, the key differences between the methods are the assumptions made about the underlying genetic architecture and the distributions of true effect sizes, with 158 159 Bayesian methods setting some priors for these distributions. Several methods employ an LD 160 reference sample to determine LD between SNPs. Here, we use EUR of the 1000 Genomes 161 Project as the LD reference, unless the method software provides an LD reference. In some 162 methods the PGS calculated in a target cohort requires estimates of parameter values, which need to be estimated by application of the PGS method to a tuning cohort (also not included 163 164 in the discovery GWAS sample) using a range of parameter estimates, then selecting the parameter estimates that maximizes prediction in that tuning cohort. In all methods, once the 165 SNPs and  $\hat{b}_i$  have been decided, PLINK --score is used to calculate the PGS in the target 166 167 sample.

168

169 LD pruning and thresholding (P+T)<sup>3</sup>

170 In the P+T method GWAS summary statistics are pruned to be approximately independent

171 using a LD threshold,  $r^2$ . From this quasi-independent genome-wide SNP list, SNPs are

172	selected by thresholding on a pre-specified association p-value, Pt. We evaluated P+T as
173	implemented in Ricopili <sup>31</sup> which uses PLINK <sup>32</sup> to prune the SNP set using $r^2 = 0.1$ within
174	500 kb windows, and $P_t \in$ (5e-08, 1e-06, 1e-04, 1e-03, 0.01, 0.05, 0.1, 0.2, 0.5, 1), where $P_t = 1$
175	means that all SNPs from the LD-pruned list are included. In applications of P+T it is
176	common for results from the most associated $P_t$ to be reported (including the application in
177	the software PRSice <sup>33</sup> which uses a continuous $P_t$ range), but this approach utilises
178	information from the target cohort and hence introduces a form of winner's curse. Here, the
179	Pt threshold applied in target cohorts is the Pt threshold that maximised prediction in the
180	tuning cohort.

181

182 SBLUP<sup>12</sup>

SBLUP is a method that re-scales the GWAS SNP effect estimates using an external LD 183 reference panel to transform the ordinary least-squares estimates to approximate the best 184 185 linear unbiased prediction (BLUP) solutions. This method assumes an infinitesimal model 186 where SNP effects are drawn from a normal distribution. All genome-wide SNPs are used to 187 build the PGS. Hence, for example, consider a genomic region with a single causal variant 188 but with many SNPs in the region correlated with the causal variant and correlated with each 189 other. In this case the effect size estimate is "smeared" across the correlated SNPs, but with 190 the total contribution to risk expected to represent the best estimate of the signal from the 191 underlying causal variant. This method is implemented within the software package GCTA<sup>34</sup>. 192

193 LDpred and LDpred-inf <sup>13</sup>

While P+T uses arbitrary LD and p-value thresholds for selection of SNPs, LDpred tries to
optimise this step in a Bayesian framework. The method uses the GWAS summary statistics
and LD information from the external LD reference sample to infer the posterior mean effect

197	size of each SNP, conditioning on the SNP effect estimates of other correlated SNPs. This
198	method assumes a point-normal prior on the distribution of SNP effects such that only a
199	fraction of SNPs with non-zero estimated effects are selected for inclusion in the PGS. The
200	default parameter setting for the fractions of causal SNPs ( $\pi$ , but denoted p in the original
201	paper) were used in the tuning cohort: $\pi \in \{1 \text{ (i.e. all SNPs)}, 0.3, 0.1, 0.03, 0.01, 0.003, and \}$
202	$0.001$ }, with an LD radius of M/3000 (M is the number of SNPs) to obtain local LD
203	information, as suggested by the authors <sup>13</sup> . The $\pi$ value that maximised the prediction in the
204	tuning sample was applied in the target sample; the $\pi$ value can differ between target cohorts
205	even though the same tuning cohort is used, reflecting the properties of the discovery sample
206	which may change with each left-out target sample. When $\pi=1$ the method is called LDpred-
207	Inf and is equivalent to SBLUP (the concordance of results was checked, Table S7).
208	
209	LDpred-funct <sup>14</sup>
210	LDpred-funct is an extension of the LDpred-inf (SBLUP equivalent) model but leverages
211	trait-specific functional enrichments relative to the baseline-LD model <sup>35</sup> to up/down-weight
212	SNP effects. The functional annotations include coding, conserved, regulatory and LD-
213	related annotation. In the baseline-LD model, the enrichment of each category is jointly
214	calculated via stratified LD score regression <sup>36</sup> . LDpred-funct has a non-infinitesimal model
215	version, but in pilot analyses we found LDpred-Inf performed better than LDpred and hence
216	only considered the LDpred-funct infinitesimal model. Thus, we continued only with the
217	infinitesimal model version.
218	
210	DRS-CS and DRS-CS-auto <sup>15</sup>

PRS-CS is also built under a Bayesian regression framework. Unlike LDpred which assumes
a point-normal distribution as a prior, which is discrete, PRS-CS assumes a continuous

shrinkage prior on the SNP effects. PRS-CS was implemented using the default setting and with the LD reference panel provided with the PRS-CS software, which is computed using the 1000 Genomes samples and HapMap3 SNPs. In PRS-CS, for the global scaling parameter which is applied to all SNP effects  $\phi$ , the search grid is  $\phi^{1/2} \in \{0.0001, 0.001, 0.01, 0.1, 1\}$ , The  $\phi$  that produces the best predictive performance in a tuning data set is selected for use in the target sample. In PRS-CS-auto,  $\phi$  is automatically learnt from GWAS summary statistics and no tunning sample is needed.

229

230 SBayesR

231 SBayesR is a method that re-scales the GWAS SNP effect estimates based on Bayesian 232 multiple regression. SBayesR assumes that the standardised SNP effects are drawn from a 233 mixture of four zero-mean normal distributions with different variances (one of the variances is zero, with a probability of  $\pi_1$ ), indicating that only a fraction of SNPs  $(1-\pi_1)$  have non-zero 234 235 estimated effects which contribute to the phenotype. Moreover, the contributions of SNPs in 236 different distributions differ because of different variances. Here, we evaluated SBayesR in 237 the default setting. For the LD reference, we used the same sparse LD matrix as the one used in Lloyd-Jones et al.<sup>16</sup>, where the LD matrix was built based on the HapMap3 SNPs of 238 239 randomly selected and unrelated 50K UK Biobank individuals. Whereas LDpred estimates 240  $\pi$  from a tuning sample, SBayesR estimates  $\pi$  from the GWAS discovery sample, so no tuning sample is needed. 241

242

243 Evaluation of out-of-sample prediction

244 The accuracy of prediction in each target cohort was quantified by 1) Area under the receiver

245 operator characteristic curve (AUC; R library pROC). AUC can be interpreted as a

246 probability that a case ranks higher than a control. 2) The proportion of variance on the

247	liability scale explained by PGS <sup>37</sup> . We used the population lifetime risk of SCZ and MDD as
248	1% and 15% respectively to convert the variance explained in a linear regression to the
249	liability scale <sup>20; 23; 38</sup> . 3) Odds ratio (OR) of tenth PGS decile relative to the first decile. 4)
250	Odds ratio of tenth PGS decile relative to those ranked in the middle of the PGS distribution,
251	which is calculated as the average of OR of tenth decile relative to fifth and sixth decile. 5)
252	Standard deviation unit increase in cases. The PGS in each target cohort were scaled by
253	standardising the PGS of controls and applying the standardisation to cases:
254	$\frac{PGS_{case}-mean(PGS_{control})}{SD(PGS_{control})}$ , where SD is standard deviation. This does not impact PGS
255	evaluation statistics but simply means that PGS are in SD units for all cohorts. We compare
256	the median value for evaluation statistics 3 and 4, because they are significantly different
257	from a normal distribution based on a Shapiro-Wilk Normality Test. The regression analyses
258	for evaluation statistics 2-4 include 6 ancestry principal components as covariates. These
259	covariates are not included in the AUC model and the standard deviation unit increase in
260	cases model. To illustrate the impact on results, for SCZ given the SBayesR mean variance in
261	liability of 9.9% and lifetime risk of 0.01 the AUC expected from normal distribution
262	theory <sup>39</sup> is 0.730, compared to the mean reported of 0.733. For MDD given the variance in
263	liability of 4.0% and lifetime risk of 0.15 the expected AUC is 0.603 compared to the mean
264	reported of 0.601.

265

# 266 Results

Prediction evaluation statistics based on recent PGS methods applied to SCZ across 30 study
cohorts (Figure 1, Table S3 and S4), and to MDD across 26 cohorts (Figure 2, Table S5 and
S6), show higher values for all methods over the benchmark method, P+T. The evaluation
statistics include i) area under the receiver operator characteristic curve (AUC) which can be

271 interpreted as the probability that a case ranks higher than a control, when the case and 272 control are randomly drawn; ii) mean difference between cases and controls expressed in 273 PGS standard deviation (SD) units of controls, after standardization of the PGS so that 274 controls in each target cohort have a mean of 0 and a SD of 1; iii) variance in liability explained by the PGS; iv) Odds ratio of the top 10% ranked on PGS relative to the bottom 275 276 10%; v) Odds ratio of the top 10% ranked on PGS relative to those ranking in the middle of 277 the PGS distribution; vi) difference between mean of PGS in the top 10% of cases and mean 278 PGS in top 10% of controls.

279

280 There is variability in prediction statistics across target cohorts which is not a reflection of 281 sample size (Figure S1 and Table S4 for SCZ, Figure S2 and Table S6 for MDD). To provide a benchmark in terms of power, we note that for SCZ, the mean difference in PGS 282 283 between cases and controls for the P+T method is 0.73 standard deviation units of the control 284 sample (SDU). A sample size of only 42 cases and 42 controls has 95% power to detect this 285 difference at a nominal significance threshold of 0.05; all SCZ cohorts are bigger than this. 286 For MDD, the mean difference in PGS SDU between cases and controls for the P+T method 287 is 0.30, and the power calculation requires a sample size of 290 cases and 290 controls to detect this difference; 20 (77%) of the MDD cohorts achieve this effective size. Hence, the 288 289 SCZ and MDD cohorts are well-powered for PGS evaluation. 290

291 The correlations of PGS between different methods are high (**Table S7**), but are lowest
292 between P+T and other methods (minimum 0.67). In contrast, the correlations between the
293 recent methods are always > 0.83. In theory, LDpred-Inf and SBLUP are the same method. In

294 practice, there are differences in implementation (e.g., different input parameters associated

295 with definition of LD window), generating a correlation 0.977. The differences in prediction

296 evaluation statistics between methods are small. For SCZ the AUC for all recent methods 297 other than PRS-CS-auto are significantly higher than the P+T method after Bonferroni 298 correction (p-value < 0.0018=0.05/28 (28 pair-wise comparisons between 8 methods), two-299 tailed Student's t-test). For MDD none of the differences between methods were significant. 300 For both SCZ and MDD, regardless of tuning cohorts SBayesR showed relatively better 301 performance (on average across target cohorts) than other methods on all statistics, where 302 other recent methods performed similarly (Figures 1 and 2). For variance explained on the 303 liability scale, the P+T PGS explained a mean of 6.8% across cohorts for SCZ. For SBayesR, 304 the mean was 9.9% for variance explained in liability, an increase of 46%. For MDD although the variance explained is lower in absolute terms, 2.8% for P+T vs 4.0% for 305 306 SBayesR; the latter represents a 43% increase. 307 308 We provide several evaluation statistics that focus on those in the top 10% of PGS, because 309 clinical utility of PGS for psychiatric disorders is likely to focus on individuals that are in the 310 top tail of the distribution of predicted genetic risk. The odds ratio for top vs bottom decile

are large, ranging from 13.8 for P+T to 22.5 for SBayesR for SCZ and 3 to 4 for MDD.

312 While these top vs bottom decile odds ratios (Figure 1c and 2c) are much larger than the

313 odds ratio obtained by using PGS to screen a general population (Figure 1d and 2d) or

314 patients in a healthcare system to identify people at high risk<sup>40; 41</sup>, these comparisons are

315 useful for research purposes, which could for example make cost-effective experimental

designs focussing on individuals with high vs low PGS.<sup>42</sup> The odds ratio of top 10% vs

317 middle 10% are much less impressive, up to median of 5.5 for SCZ and 2 for MDD, but more

fairly represents the value of PGS in population settings. These values can be benchmarked

319 against risk in 1<sup>st</sup> degree relatives of those affected, which are of the order of 8 for SCZ and 2

320 for MDD; low values are always expected for MDD because it is more common (lifetime risk

321	~15% compared to ~1% for SCZ). The odds ratio values are particularly high for some
322	cohorts (Table S4), because in some SCZ cohorts the bottom 10% include very few or no
323	cases, especially in cohorts with relatively small sample sizes. Since the PGS are normally
324	distributed, as expected the mean PGS for controls in the top 10% PGS is $\sim$ 1.75 SD units
325	(K=0.10, t=qnorm(1-K), z=dnorm(t), mean value of top 10% of a normal distribution =z/K),
326	whereas the top 10% of cases have mean value of 2.63 control sample SD units for SCZ
327	cases and 2.09 control sample SD units for MDD cases, using SBayesR. These mean values

328 of the top 10% in cases equate to expectations from the population of the top 1.1% and top

- 329 4.7% for SCZ and MDD, respectively.
- 330

331 The impact of tuning cohort. Three methods (i.e., P+T, LDpred and PRC-CS) use tuning 332 cohorts to determine key parameters for application of the method into the target cohorts. 333 Tuning parameters impact results in two ways. First, the parameters may be dependent on the 334 choice of tuning cohort. Second, the discovery GWAS sample may be reduced in size (and 335 hence power) if a tuning cohort needs to be excluded from the discovery GWAS. In all our 336 analyses the tuning cohort is excluded from all GWAS discovery samples so that GWAS 337 discovery sample is not variable across methods for each target cohort. A sensitivity analyses that used the SCZ cohorts of msaf (Ncase= 327, Ncontrol= 139), gras (Ncase= 1086, 338 339 Ncontrol= 1232) or swe6 (Ncase= 1094, Ncontrol= 1219) as the tuning sample instead of 340 cohort lie2 (Ncase= 137, Ncontrol= 269) show that the tuning cohort can have considerable 341 impact (Figure 3 and Figures S3-5). In our results, the tuning cohort that generates higher 342 PGS is method dependent and differs between cohorts. Although methods SBLUP, LDpred-343 Inf, LDpred-funct, PRS-CS-auto and SBayesR require no tuning cohort, they serve as a 344 benchmark, since the differences in their results reflect differences in the changed discovery

samples (e.g., msaf is in the discovery sample, when lie2 is the tuning cohort, and *vice versa*),
as well as the stochasticity inherent in the Gibbs sampling of Bayesian methods.

347

348 The impact of MAF/INFO threshold. A MAF threshold of 0.1 and a INFO threshold of 0.9 are used to be consistent with applications in the PGC SCZ<sup>23</sup> and PGC MDD<sup>20</sup> studies, which 349 350 had been imposed recognising that these thresholds generated more robust PGS results than 351 using lower threshold values. In the second sensitivity analysis applied to the SCZ data, the 352 MAF threshold was relaxed to 0.05 (Figure 4) and to 0.01 (Figure S6). The prediction 353 evaluation statistics increase for some cohorts and decrease for others. SBLUP, PRS-CS, 354 PRS-CS-auto and SBayesR are less affected than P+T, LDpred-Inf, LDpred-funct and 355 LDpred. For QC threshold of MAF < 0.01, the differences in AUC have a similar trend 356 compared to using MAF<0.05, but with greater variability (Figure S6). The effects of MAF 357 thresholds vary between cohorts, although the use of lower MAF threshold tends to generate 358 higher AUC for the larger target samples. Across target cohorts, different evaluation statistics 359 were almost identical when including less common SNPs (Table S3). Relaxing the INFO 360 score to 0.3 has a negligible effect (Figure S7).

### 361 Discussion

Comparison of PGS risk prediction methods showed that all recent methods had higher prediction evaluation statistics over the benchmark P+T method for SCZ and MDD. While the differences between the recent methods were small, we found that SBayesR consistently ranked highest. Given that the PGS is a sum of many small effects, a normal distribution of PGS in a population is expected (and observed **Figures S8-S11**). In idealised data, such as the relatively simple simulation scenarios usually considered in method development, all evaluation statistics should rank the same, but with real data sets this is not guaranteed. This

369 is the motivation for considering a range of evaluation statistics. Our focus on statistics for 370 those in the top 10% of PGS is partly motivated by potential clinical utility. In the context of psychiatry, it is likely that this will focus on people presenting in a prodromal state with 371 372 clinical symptoms that have not yet crystallised to a specific diagnosis<sup>10; 43</sup>. High PGS in 373 those presenting to clinics could help tilt the clinical decision-making towards closer 374 monitoring or earlier intervention. Since a genetic-based predictor only predicts part of the 375 risk of disease, and since a PGS only predicts part of the genetic contribution to disease it is 376 acknowledged that PGS cannot be fully accurate predictors. Nonetheless, PGS, in 377 combination with clinical risk factors, could make a useful contribution to risk prediction. 378 379 In sensitivity analyses that used different quality criteria for SNPs e.g. MAF of 0.01 vs 0.05, 380 INFO of 0.3 vs 0.9, we concluded that, currently, there is little to be gained in PGS from 381 including SNPs with MAF < 0.10 and INFO < 0.9 for the diseases/dataset studied (Table S8 382 and S9). This result may seem counter-intuitive since variants with low MAF are expected to 383 play an important role in common disease, and some may be expected to have larger effect sizes than more common variants<sup>44; 45</sup>. However, sampling variance is a function of allele 384 385 frequency (var(y)/(2\*MAF(1-MAF)\*n)), where n is sample size), such that a variant of MAF =0.01 has sampling variance 25 times greater than a variant of MAF=0.5. Moreover, in real 386 387 data sets cohort sample size and technical artefacts can accumulate to increase error in effect 388 size estimates particularly of low frequency variants. Our conclusion that little is gained from 389 including variants of MAF < 0.1 and reducing INFO threshold needs to be revisited as larger 390 discovery samples and larger target cohorts accumulate.

391

For both SCZ and MDD, while all recent methods had similar performance, SBayesR saw the
highest prediction accuracy in most of the comparisons. Although SCZ and MDD both have a

394 highly polygenic genetic architecture, we have recently shown that SBayesR outperforms other methods for two less polygenic diseases, Alzheimer's<sup>46</sup> (which includes the APOE 395 locus which has a very large effect size) and ALS<sup>47</sup> (for which there is evidence of greater 396 importance of low MAF variants compared to SCZ<sup>48</sup>). The original SBayesR publication 397 398 showed that in both simulations and applications to real data, the method performed well 399 across a range of traits with different underlying genetic architectures, which is because 400 SBayesR can fit essentially any underlying architecture and other methods are special cases 401 of the SBayesR model, except PRS-CS which uses different distributional approaches (Table 402 1). We note that we did not consider a version of P+T that has been shown to have higher out of sample prediction compared to the standard implementation<sup>11</sup>. This method conducts a 403 404 grid search in a tuning cohort to determine LD  $r^2$  and INFO score thresholds for SNPs as well 405 as the p-value threshold. We chose to implement only the basic, commonly used P+T 406 method, and specifically as implemented in published PGC studies. Moreover, many of the 407 methods implemented here address optimum SNP selection from a methodological approach 408 rather than grid search approach. We note that here we only considered the infinitesimal 409 model version of LDpred-funct, because we have already found no advantage of LDpred over 410 LDpred-inf in the preliminary analyses. For traits and diseases of other genetic architecture 411 parameters of LDpref-funct should be investigated, although in the updated LDpred-funct preprint<sup>49</sup>, SBayesR was found to perform well across a range of quantitative and binary 412 413 traits. We do note that SBayesR expects effect size estimates and their standard errors to have 414 properties consistent with the sample size and with the LD patterns imposed from an external 415 reference panel. If GWAS summary statistics have non-ideal properties (perhaps resulting 416 from meta-analysis errors or approximations) then SBayesR may not achieve converged 417 solutions. Last, we note that the comparison of methods uses only study samples of European 418 ancestry. More research is needed to understand the properties of prediction methods within

other ancestries and across ancestries, given potential differences in genetic architectures (in
terms of number, frequencies and effect sizes of causal variants) and LD between measured
variants and causal variants<sup>50; 51</sup>. Such research is dependent on the availability of large
GWAS data sets from non-European ancestries; currently there is considerable effort to
increase GWAS sample collection across world-wide population groups to address this
concern<sup>50-52</sup>.

425

426 All recent methods are compared using their default parameters settings. An optimum setting 427 of each method could potentially increase the prediction accuracy. For example, in sensitivity analyses we found that LDpred sees higher prediction accuracy when increasing the length of 428 429 MCMC chain, while PRS-CS-auto and SBayesR results are not impacted by increasing the 430 MCMC chain length beyond the default settings (Table S10). This result agrees with the recent revision of LDpred, LDpred2<sup>53</sup>. The underlying model and assumptions about the SNP 431 432 effect distribution are unchanged, but higher prediction accuracy is reported for longer 433 MCMC chain and larger LD windows. Most likely the optimum parameter settings are trait 434 (genetic architecture) dependent<sup>11</sup>. Hence, we conclude that a key advantage of SBayesR is 435 that there is no need for the user to tune or select model or software parameters. Moreover, it does not need a tuning cohort to derive SNP effect weights but learns the genetic architecture 436 437 from the properties of the GWAS results. A third key advantage of SBayesR is computational 438 speed. Using one CPU, it takes approximately 2 hours to generate SNP weights based on 439 each discovery sample and predict into the left-out-cohort, compared to PRS-CS which needs 440 40 hours using 5 CPUs (the CPU number is fixed in the PRS-CS software). Last, given that 441 SBayesR uses only HapMap3 SNPs that are mostly well-imputed it should be possible to 442 provide these SBayesR SNP weights as part of a GWAS pipeline to apply in external target 443 samples.

# 444 Supplemental Data

The Supplemental Data include 11 figures and consortium members.

446

## 447 Acknowledgements

- 448 We acknowledge funding from the National health and Medical Research Council
- 449 (1173790,1078901,108788 (NRW),1113400 (NRW, PMV)) and the Australian Research
- 450 Council (FL180100072 (PMV)).
- 451 This work would not have been possible without the contributions of the investigators who
- 452 comprise the PGC-SCZ and PGC-MDD working group. For a full list of acknowledgments of
- 453 all individual cohorts included in PGC-SCZ and PGC-MDD, please see the original
- 454 publications. The PGC has received major funding from the US National Institute of Mental
- 455 Health and the US National Institute of Drug Abuse (U01 MH109528 and U01 MH1095320).
- 456 We thank the customers, research participants and employees of 23andMe for making this
- 457 work possible. The study protocol used by 23andMe was approved by an external AAHRPP-
- 458 accredited institutional review board.
- 459 The Münster cohort was funded by the German Research Foundation (DFG, grant FOR2107
- 460 DA1151/5-1 and DA1151/5-2 to U.D.; SFB-TRR58, Projects C09 and Z02 to U.D.) and the
- 461 Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster
- 462 (grant Dan3/012/17 to U.D.).
- 463 Some data used in this study were obtained from dbGaP. dbGaP accession phs000021:
- 464 funding support for the Genome-Wide Association of Schizophrenia Study was provided by
- the National Institute of Mental Health (R01 MH67257, R01 MH59588, R01 MH59571, R01
- 466 MH59565, R01 MH59587, R01 MH60870, R01 MH59566, R01 MH59586, R01 MH61675,
- 467 R01 MH60879, R01 MH81800, U01 MH46276, U01 MH46289, U01 MH46318, U01

468 MH79469, and U01 MH79470), and the genotyping of samples was provided through the

- 469 Genetic Association Information Network (GAIN). Samples and associated phenotype data
- 470 for the Genome-Wide Association of Schizophrenia Study were provided by the Molecular
- 471 Genetics of Schizophrenia Collaboration (principal investigator P. V. Gejman, Evanston
- 472 Northwestern Healthcare (ENH) and Northwestern University, Evanston, IL, USA). dbGaP
- 473 accession phs000196: this work used in part data from the NINDS dbGaP database from the
- 474 CIDR: NGRC PARKINSON'S DISEASE STUDY. dbGaP accession phs000187: High-
- 475 Density SNP Association Analysis of Melanoma: Case–Control and Outcomes Investigation.
- 476 Research support to collect data and develop an application to support this project was
- 477 provided by P50 CA093459, P50 CA097007, R01 ES011740, and R01 CA133996 from the
- 478 NIH.
- 479 Statistical analyses were carried out on the Genetic Cluster Computer
- 480 (http://www.geneticcluster.org) hosted by SURFsara and financially supported by the
- 481 Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the
- 482 Dutch Brain Foundation and the VU University Amsterdam.

### 483 **Declaration of Interests**

484 The authors declare no competing interests.

# 485 **References**

- 486
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
   487
- 2. Palk, A.C., Dalvie, S., De Vries, J., Martin, A.R., and Stein, D.J. (2019). Potential use of
  clinical polygenic risk scores in psychiatry–ethical implications and communicating
  high polygenic risk. Philos. Ethics Humanit. Med. 14, 4.
- 491 3. Wray, N.R., Goddard, M.E., and Visscher, P.M. (2007). Prediction of individual genetic risk
  492 to disease from genome-wide association studies. Genome Res. 17, 1520-1528.
- 493 4. Jenkins, M.A., Win, A.K., Dowty, J.G., MacInnis, R.J., Makalic, E., Schmidt, D.F., Dite, G.S., 494 Kapuscinski, M., Clendenning, M., and Rosty, C. (2019). Ability of known

495	susceptibility SNPs to predict colorectal cancer risk for persons with and without a
496	family history. Fam. Cancer 18, 389-397.
497	5. Lee, A., Mavaddat, N., Wilcox, A.N., Cunningham, A.P., Carver, T., Hartley, S., de Villiers,
498	C.B., Izquierdo, A., Simard, J., and Schmidt, M.K. (2019). BOADICEA: a comprehensive
499	breast cancer risk prediction model incorporating genetic and non-genetic risk
500	factors. Genet. Med. 21, 1708.
501	6. Khera, A.V., Chaffin, M., Aragam, K.G., Haas, M.E., Roselli, C., Choi, S.H., Natarajan, P.,
502	Lander, E.S., Lubitz, S.A., and Ellinor, P.T. (2018). Genome-wide polygenic scores for
503	common diseases identify individuals with risk equivalent to monogenic mutations.
504	Nat. Genet. 50, 1219-1224.
505	7. Lloyd-Jones, D.M., Wilson, P.W.F., Larson, M.G., Beiser, A., Leip, E.P., D'Agostino, R.B., and
506	Levy, D. (2004). Framingham risk score and prediction of lifetime risk for coronary
507	heart disease. Am. J. Cardiol. 94, 20-24.
508	8. McCarthy, M.I., and Mahajan, A. (2018). The value of genetic risk scores in precision
509	medicine for diabetes. Expert Rev. Precis. Med. Drug Dev. 3.
510	9. Torkamani, A., Wineinger, N.E., and Topol, E.J. (2018). The personal and clinical utility of
511	polygenic risk scores. Nat. Rev. Genet. 19, 581.
512	10. Murray, G.K., Lin, T., Austin, J., McGrath, J.J., Hickie, Ian B., and Wray, N.R. (2020).
513	Polygenic risk scores - could they be useful in psychiatry? Submitted.
514	11. Privé, F., Vilhjálmsson, B.J., Aschard, H., and Blum, M.G.B. (2019). Making the most of
515	Clumping and Thresholding for polygenic scores, Am. J. Hum. Genet. 105, 1213-1221.
516	12. Robinson, M.R., Kleinman, A., Graff, M., Vinkhuvzen, A.A.E., Couper, D., Miller, M.B.,
517	Pevrot, W.L. Abdellaoui, A. Zietsch, B.P., and Nolte, I.M. (2017), Genetic evidence of
518	assortative mating in humans. Nat. Hum. Behav. 1, 0016.
519	13. Vilhiálmsson, B.J., Yang, J., Finucane, H.K., Gusev, A., Lindström, S., Ripke, S., Genovese,
520	G. Loh, PR., Bhatia, G., and Do, R. (2015). Modeling linkage disequilibrium
521	increases accuracy of polygenic risk scores. Am. J. Hum. Genet. 97, 576-592.
522	14 Marquez-Luna C Gazal S Joh P-R Eurlotte N Auton A Price A L and and Me
523	Research T (2018) Modeling functional enrichment improves polygenic prediction
524	accuracy in LIK Biobank and 23andMe data sets bioRxiv 375337
525	15 Ge T Chen C -Y Ni Y Feng Y -C A and Smoller I W (2019) Polygenic prediction via
526	Bayesian regression and continuous shrinkage priors Nat Commun 10 1776
520 527	16 Llovd-Jones J. R. Zeng J. Sidorenko J. Yengo J. Moser G. Kemper K.F. Wang H.
528	Zheng Z Magi R and Esko T (2019) Improved polygenic prediction by Bayesian
520	multiple regression on summary statistics highwiy
530	17 Chatteries N. Shi L. and García-Closas M. (2016). Developing and evaluating polygenic
531	rick prediction models for stratified disease prevention. Nat. Rev. Genet. 17, 392
537	18 The International Schizophronia Consortium (2020) Manuscript in proparation
522	10. Dardiñas A.E. Holmans D. Docklington A.L. Essott Driso V. Pinko S. Carrora N.
524	19. Parulias, A.F., Holmans, F., Fockington, A.J., Escott-Frice, V., Kipke, S., Carrera, N.,
525	Legge, S.E., Dishop, S., Cameron, D., and Hamshere, M.L. (2016). Common
535 526	schizophrenia alleles are enficited in mutation-intolerant genes and in regions under
330 527	Strong background selection. Nat. Genet. 50, 381-389.
55/ 520	20. Wray, N.K., Kipke, S., Mattheisen, M., Trzaskowski, M., Byrne, E.M., Abdellaoul, A.,
538	Adams, IVI.J., Agerbo, E., AIr, T.IVI., and Andiauer, T.M.F. (2018). Genome-wide
539	association analyses identify 44 risk variants and refine the genetic architecture of
540	major depression. Nat. Genet. 50, 668.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.10.20192310; this version posted September 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

541 21. Howard, D.M., Adams, M.J., Clarke, T.-K., Hafferty, J.D., Gibson, J., Shirali, M., Coleman, 542 J.R.I., Hagenaars, S.P., Ward, J., and Wigmore, E.M. (2019). Genome-wide meta-543 analysis of depression identifies 102 independent variants and highlights the 544 importance of the prefrontal brain regions. Nat. Neurosci. 22, 343. 545 22. Trzaskowski, M., Mehta, D., Peyrot, W.J., Hawkes, D., Davies, D., Howard, D.M., Kemper, 546 K.E., Sidorenko, J., Maier, R., and Ripke, S. (2019). Quantifying between-cohort and 547 between-sex genetic heterogeneity in major depressive disorder. American Journal 548 of Medical Genetics Part B: Neuropsychiatric Genetics 180, 439-447. 549 23. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological 550 insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427. 551 24. Howard, D.M., Adams, M.J., Shirali, M., Clarke, T.-K., Marioni, R.E., Davies, G., Coleman, 552 J.R.I., Alloza, C., Shen, X., and Barbu, M.C. (2018). Genome-wide association study of 553 depression phenotypes in UK Biobank identifies variants in excitatory synaptic 554 pathways. Nat. Commun. 9, 1-10. 555 25. Hyde, C.L., Nagle, M.W., Tian, C., Chen, X., Paciga, S.A., Wendland, J.R., Tung, J.Y., Hinds, 556 D.A., Perlis, R.H., and Winslow, A.R. (2016). Identification of 15 genetic loci 557 associated with risk of major depression in individuals of European descent. Nat. 558 Genet. 48, 1031. 559 26. Banda, Y., Kvale, M.N., Hoffmann, T.J., Hesselson, S.E., Ranatunga, D., Tang, H., Sabatti, 560 C., Croen, L.A., Dispensa, B.P., and Henderson, M. (2015). Characterizing 561 race/ethnicity and genetic ancestry for 100,000 subjects in the Genetic Epidemiology 562 Research on Adult Health and Aging (GERA) cohort. Genetics 200, 1285-1295. 563 27. Pedersen, C.B., Bybjerg-Grauholm, J., Pedersen, M.G., Grove, J., Agerbo, E., Baekvad-564 Hansen, M., Poulsen, J.B., Hansen, C.S., McGrath, J.J., and Als, T.D. (2018). The 565 iPSYCH2012 case-cohort sample: new directions for unravelling genetic and 566 environmental architectures of severe mental disorders. Mol. Psychiatry 23, 6-14. 567 28. Ripke, S., Wray, N.R., Lewis, C.M., Hamilton, S.P., Weissman, M.M., Breen, G., Byrne, 568 E.M., Blackwood, D.H.R., Boomsma, D.I., and Cichon, S. (2013). A mega-analysis of 569 genome-wide association studies for major depressive disorder. Mol. Psychiatry 18, 570 497-511. 571 29. Smith, B.H., Campbell, A., Linksted, P., Fitzpatrick, B., Jackson, C., Kerr, S.M., Deary, I.J., 572 MacIntyre, D.J., Campbell, H., and McGilchrist, M. (2012). Cohort Profile: Generation 573 Scotland: Scottish Family Health Study (GS: SFHS). The study, its participants and 574 their potential for genetic research on health and illness. Int. J. Epidemiol. 42, 689-575 700. 576 30. Fernandez-Pujals, A.M., Adams, M.J., Thomson, P., McKechanie, A.G., Blackwood, D.H.R., 577 Smith, B.H., Dominiczak, A.F., Morris, A.D., Matthews, K., and Campbell, A. (2015). 578 Epidemiology and heritability of major depressive disorder, stratified by age of 579 onset, sex, and illness course in Generation Scotland: Scottish Family Health Study 580 (GS: SFHS). PLoS One 10, e0142197. 581 31. Lam, M., Awasthi, S., Watson, H.J., Goldstein, J., Panagiotaropoulou, G., Trubetskoy, V., 582 Karlsson, R., Frei, O., Fan, C.-C., De Witte, W., et al. (2019). RICOPILI: Rapid 583 Imputation for COnsortias PIpeLIne. Bioinformatics. 584 32. Chang, C.C., Chow, C.C., Tellier, L.C.A.M., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). 585 Second-generation PLINK : rising to the challenge of larger and richer datasets. 586 GigaScience. 4.

- 587 33. Euesden, J., Lewis, C.M., and O'Reilly, P.F. (2015). PRSice: polygenic risk score software. 588 Bioinformatics 31, 1466-1468.
- 589 34. Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011). GCTA: A tool for genome-590 wide complex trait analysis. Am. J. Hum. Genet. 88, 76-82.
- 591 35. Gazal, S., Finucane, H.K., Furlotte, N.A., Loh, P.-R., Palamara, P.F., Liu, X., Schoech, A., 592 Bulik-Sullivan, B., Neale, B.M., and Gusev, A. (2017). Linkage disequilibrium-593 dependent architecture of human complex traits shows action of negative selection. 594 Nat. Genet. 49, 1421.
- 595 36. Finucane, H.K., Bulik-sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P.-r., Anttila, V., 596 Xu, H., Zang, C., Farh, K., et al. (2015). Partitioning heritability by functional 597 annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228-598 1235.
- 599 37. Lee, S.H., Goddard, M.E., Wray, N.R., and Visscher, P.M. (2012). A better coefficient of 600 determination for genetic profile analysis. Genet. Epidemiol. 36, 214-224.
- 601 38. Lee, S.H., Wray, N.R., Goddard, M.E., and Visscher, P.M. (2011). Estimating missing 602 heritability for disease from genome-wide association studies. Am. J. Hum. Genet. 603 88, 294-305.
- 604 39. Wray, N.R., Lin, T., Austin, J., McGrath, J.J., Hickie, Ian B., Murray, G.K., and Visscher, 605 P.M. (2020). Polygenic risk scores – from basic science to clinical application: a 606 primer. JAMA Psychiatry (In press).
- 607 40. Zheutlin, A.B., Dennis, J., Karlsson Linnér, R., Moscati, A., Restrepo, N., Straub, P., 608 Ruderfer, D., Castro, V.M., Chen, C.-Y., and Ge, T. (2019). Penetrance and pleiotropy 609 of polygenic risk scores for schizophrenia in 106,160 patients across four health care 610 systems. Am. J. Psychiatry 176, 846-855.
- 611 41. Binder, E.B. (2019). Polygenic Risk Scores in Schizophrenia: Ready for the Real World? 612 Am. J. Psychiatry 170, 783-784.
- 613 42. Rehbach, K., Zhang, H., Das, D., Abdollahi, S.S., Prorok, T., Ghosh, S., Weintraub, S., 614 Genovese, G., Powell, S., and Lund, A. (2020). Publicly available hiPSC lines with 615 extreme polygenic risk scores for modeling schizophrenia. bioRxiv.
- 616 43. Perkins, D.O., Olde Loohuis, L., Barbee, J., Ford, J., Jeffries, C.D., Addington, J., Bearden, 617 C.E., Cadenhead, K.S., Cannon, T.D., and Cornblatt, B.A. (2020). Polygenic risk score 618 contribution to psychosis prediction in a target population of persons at clinical high 619 risk. Am. J. Psychiatry 177, 155-163.
- 620 44. Park, J.-H., Gail, M.H., Weinberg, C.R., Carroll, R.J., Chung, C.C., Wang, Z., Chanock, S.J., 621 Fraumeni, J.F., and Chatterjee, N. (2011). Distribution of allele frequencies and effect 622 sizes and their interrelationships for common genetic susceptibility variants. 623 Proceedings of the National Academy of Sciences 108, 18026-18031.
- 624 45. Bomba, L., Walter, K., and Soranzo, N. (2017). The impact of rare and low-frequency 625 genetic variants in common disease. Genome Biol. 18, 77.
- 626 46. Zhang, Q., Visscher, P.M., and McRae, A.F. (2020). Risk prediction of late-onset 627 Alzheimer's disease implies an oligogenic architecture. Submitted.
- 628 47. Restuadi, R., Garton, F.C., Benyamin, B., and Lin, T. (2020). Polygenic Risk Score Analysis 629 for Amyotrophic Lateral Sclerosis leveraging Cognitive Performance, Educational 630 Attainment and Schizophrenia. Eur. J of Hum. Genet.
- 631 48. van Rheenen, W., Shatunov, A., Dekker, A.M., McLaughlin, R.L., Diekstra, F.P., Pulit, S.L., 632 van der Spek, R.A., Võsa, U., de Jong, S., and Robinson, M.R. (2016). PARALS Registry. 633 SLALOM Group. SLAP Registry. FALS Sequencing Consortium. SLAGEN Consortium.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.10.20192310; this version posted September 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

# perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 634 NNIPPS Study Group Genome-wide association analyses identify new risk variants 635 and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 48, 1043-636 1048. 637 49. Márquez-Luna, C., Gazal, S., Loh, P.-R., Kim, S.S., and Furlotte, N. LDpred-funct: 638 incorporating functional priors improves polygenic prediction accuracy in UK Biobank 639 and 23andMe data sets.
- 640 50. Martin, A.R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B.M., and Daly, M.J. (2019). 641 Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. 642 Genet. 51, 584.
- 643 51. Peterson, R.E., Kuchenbaecker, K., Walters, R.K., Chen, C.Y., Popejoy, A.B., Periyasamy, 644 S., Lam, M., Iyegbe, C., Strawbridge, R.J., Brick, L., et al. (2019). Genome-wide
- 645 Association Studies in Ancestrally Diverse Populations: Opportunities, Methods, 646 Pitfalls, and Recommendations. Cell 179, 589-603.
- 647 52. Karczewski, K.J., and Martin, A.R. (2020). Analytic and Translational Genetics. Annu. Rev. 648 Biomed. Data Sci. 3.
- 649 53. Privé, F., Arbel, J., and Vilhjálmsson, B.J. (2020). LDpred2: better, faster, stronger.
- 650 BioRxiv.
- 651

It is made available under a

#### Figure 652



653 654

Figure 1. Results from prediction of SCZ case/control status using different PGS

655 methods.



663		an infinitesimal model assumption. Light green shows the methods using a tuning cohort
664		to determine the genetic architecture of a trait. Dark green shows the methods learning the
665		genetic architecture from discovery sample, without using a tuning cohort.
666	b)	The proportion of variance explained by PGS on the scale of liability, assuming a
667		population lifetime risk of 1%.
668	c)	The odds ratio when considering the odds of being a case comparing the top 10% vs
669		bottom 10% of PGS. The number below each violin is the median OR estimated by each
670		method, followed by its rank.
671	d)	The odds ratio when considering the odds of being a case comparing the top 10% vs those
672		in the middle of the PGS distribution, calculated as the averaged odds ratio of the top
673		10% ranked on PGS relative to the 5 <sup>th</sup> decile and 6 <sup>th</sup> decile. The number below each
674		violin is the median OR estimated by each method, followed by its rank.
675	e)	The mean of the PGS for the top 10% cases (coloured boxes) and for the top 10% of
676		controls (grey boxes) in PGS standard deviation (SD) unit scale so that controls have
677		mean PGS of zero and SD of 1.
678	f)	This table shows the percentages of the number of cohorts (out of 30) where SBayesR
679		showed a higher prediction metric compared to different methods. AUC: Area under
680		curve; Variance explained: The proportion of variance explained by PGS in liability
681		scale; OR TvsB: odds ratio, comparing the top 10% vs bottom 10% of PGS; OR TvsM:
682		odds ratio, comparing the top 10% vs those in the middle of the PGS distribution; SD
683		increase: standard deviation units increasing of the PGS for the top 10% cases.



684



687 Similar to the caption of Figure 1, but the predictors were constructed from GWAS summary

- statistics of UK Biobank<sup>15</sup>, 23andMe<sup>16</sup>, GERA<sup>17</sup>, iPSYCH<sup>18</sup>, deCODE<sup>19</sup>, GenScotland<sup>20,21</sup>, 688
- 689 PGC-MDD29 excluding the target cohort. The target cohorts comprised 26 of the 29 cohorts
- 690 in MDD29. A cohort from Muenster, not included in the MDD29 was used as the tuning
- 691 sample. The assumed population lifetime risk was 15% when estimating the proportion of
- 692 variance explained by MDD PGS in liability scale.



693

#### Figure 3. Sensitivity analyses using different tuning cohorts. 694

695 Differences in AUC of a PGS method when using different tuning cohorts. The different bars

696 in each method (x-axis) refer to different validation cohorts ordered by sample size. The y-

- 697 axis is the AUC difference when using alternative tuning cohort (i.e. msaf, sew6 or gras),
- 698 compared to 'lie2'. The MAF QC threshold is 0.1. Note: SBLUP, LDpred-Inf and LDpred-
- 699 funct, PRS-CS-auto and SBayesR do not need a tuning cohort, but serve as a benchmark to
- 700 methods which need a tuning cohort. These methods differ when a different tuning cohort is
- 701 left out, because the discovery GWAS also changes.



# Figure 4. Sensitivity analyses using different MAF quality control thresholds.

- 704 Differences in AUC of a PGS method when using different MAF QC thresholds. The
- 705 different bars in each method (x-axis) refer to different validation cohorts ordered by sample
- size. The y-axis is the AUC difference between analyses using MAF < 0.05 and MAF < 0.1 as
- 707 a QC threshold. The tuning cohort is 'lie2'.

708

709 Table

711	Table 1.	Summary	of methods	used to	generate PGS
					0

Method	Distribution of SNP effects	Tuning sample	Pre-defined parameters	Parameters estimated in tuning sample
P+T	None	Yes	-	P value threshold
SBLUP	$\beta \sim N(0, \frac{h_g^2}{m})$ $h_g^2$ : SNP-heritability, <i>m</i> : number of SNPs	No	<i>M,</i> h <sup>2</sup> <sub>g</sub> , LD radius in kb	-
LDpred- Inf	Same as SBLUP	No	Sample size, LD radius in number of SNPs	-
LDpred- funct	$\beta_j \sim N(0, c\sigma_j^2)$ $\sum_{j=1}^{M} 1_{\sigma_j^2 > 0} c\sigma_j^2 = h_g^2$ , <i>c</i> is a normalizing constant $\sigma_j^2$ is the expected per SNP-heritability under the baseline-LD annotation model.	No	$h_g^2$ , Per-SNP heritability estimated from stratified LDSC, Sample size, LD radius in number of SNPs	-
LDpred	$\beta_{j} \sim \begin{cases} N(0, \frac{h_{g}^{2}}{\pi m}), & \text{with probability of } \pi \\ 0, & \text{with probability of } 1 - \pi \end{cases}$	Yes	Sample size, LD radius in number of SNPs	π
PRS-CS	$\beta_{j} \sim N(0, \frac{\sigma^{2}}{n} \psi_{j})$ $\psi_{j} \sim G(a, \delta_{j})$ $\delta_{j} \sim G(b, \phi)$ $\phi \text{ is a global scaling parameter.}$ n  is sample size G  is a Gamma distribution	Yes	a, b, Sample size	$\phi$
PRS-CS- auto	Same as PRS-CS, but estimates $\phi$ from the discovery GWAS.	No	a, b, Sample size	-

$$\begin{array}{c|c} \mathbf{SBayesR} & \beta_{j} \mid \pi, \sigma_{\beta}^{2} \sim \begin{cases} 0, \text{ with probability of } \pi_{1} \\ N(0, \gamma_{2}\sigma_{\beta}^{2}), \text{ with probability of } \pi_{2} \\ \vdots \\ N(0, \gamma_{c}\sigma_{\beta}^{2}), \text{ with probability of } 1 - \sum_{c=1}^{C-1} \pi_{c} \\ \sigma_{\beta}^{2} \sim Inv - \chi^{2}(4) \\ \pi_{i} \sim Dir(1) \\ \gamma_{i} \text{ are scaling parameters} \\ \hline \text{Distributions: } N: \text{ normal, } G: \text{ gamma, } Inv - \chi^{2}: \text{ inverse chi-squared distribution, } Dir: \text{Dirichlet} \end{cases}$$

\_